RVMD Revolution Medicines Inc

Price (delayed)

$34.75

Market cap

$2.55B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.93

Enterprise value

$2.23B

Highlights
The EPS has surged by 89% year-on-year and by 4% since the previous quarter
The company's equity has surged by 88% YoY and by 52% QoQ
The debt has soared by 199% YoY but it has contracted by 2.1% from the previous quarter
Revolution Medicines's net income has plunged by 121% YoY and by 16% from the previous quarter
The revenue has declined by 14% year-on-year and by 3.3% since the previous quarter

Key stats

What are the main financial stats of RVMD
Market
Shares outstanding
73.44M
Market cap
$2.55B
Enterprise value
$2.23B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.53
Price to sales (P/S)
58.87
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
53.68
Earnings
Revenue
$41.57M
EBIT
-$125.45M
EBITDA
-$118.77M
Free cash flow
-$115.2M
Per share
EPS
-$1.93
Free cash flow per share
-$1.64
Book value per share
$9.85
Revenue per share
$0.59
TBVPS
$10.46
Balance sheet
Total assets
$811.65M
Total liabilities
$89.07M
Debt
$31.99M
Equity
$722.58M
Working capital
$653.65M
Liquidity
Debt to equity
0.04
Current ratio
15.94
Quick ratio
15.77
Net debt/EBITDA
2.7
Margins
EBITDA margin
-285.7%
Gross margin
100%
Net margin
-302.7%
Operating margin
-305.6%
Efficiency
Return on assets
-20.7%
Return on equity
-24.4%
Return on invested capital
-32.8%
Return on capital employed
-16.3%
Return on sales
-301.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RVMD stock price

How has the Revolution Medicines stock price performed over time
Intraday
2.18%
1 week
6.17%
1 month
8.63%
1 year
-8.62%
YTD
-12.23%
QTD
-24.26%

Financial performance

How have Revolution Medicines's revenue and profit performed over time
Revenue
$41.57M
Gross profit
$41.57M
Operating income
-$127.01M
Net income
-$125.82M
Gross margin
100%
Net margin
-302.7%
The net margin has plunged by 157% YoY and by 20% from the previous quarter
Revolution Medicines's operating margin has plunged by 128% YoY and by 19% from the previous quarter
Revolution Medicines's net income has plunged by 121% YoY and by 16% from the previous quarter
RVMD's operating income has dropped by 96% year-on-year and by 15% since the previous quarter

Growth

What is Revolution Medicines's growth rate over time

Valuation

What is Revolution Medicines stock price valuation
P/E
N/A
P/B
3.53
P/S
58.87
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
53.68
The EPS has surged by 89% year-on-year and by 4% since the previous quarter
The company's equity has surged by 88% YoY and by 52% QoQ
The P/B is 29% lower than the last 4 quarters average of 5.0
The revenue has declined by 14% year-on-year and by 3.3% since the previous quarter
The stock's price to sales (P/S) is 8% more than its last 4 quarters average of 54.3

Efficiency

How efficient is Revolution Medicines business performance
The return on sales has dropped by 136% year-on-year and by 20% since the previous quarter
RVMD's ROA is down by 33% YoY but it is up by 2.8% QoQ
Revolution Medicines's return on equity has decreased by 33% YoY but it has increased by 4.7% QoQ
RVMD's ROIC is up by 13% year-on-year

Dividends

What is RVMD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RVMD.

Financial health

How did Revolution Medicines financials performed over time
RVMD's quick ratio has surged by 84% year-on-year and by 66% since the previous quarter
Revolution Medicines's current ratio has soared by 83% YoY and by 66% from the previous quarter
The debt is 96% less than the equity
The debt has soared by 199% YoY but it has contracted by 2.1% from the previous quarter
The company's equity has surged by 88% YoY and by 52% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.